Choline Supplementation for Cannabis Use During Pregnancy
Trial Summary
What is the purpose of this trial?
The goal of this study is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women who have used cannabis products during the current pregnancy improves the offspring\'s brain-related development during the first 3 months. Participating pregnant women will receive either phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The primary outcomes are the child\'s brain responses to sound at 4 weeks corrected age and infant behaviors at 3 months corrected age as reported by the primary caregiver. Secondary outcomes include motor, socio-emotional, language and cognitive development.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
Is choline supplementation safe for pregnant women?
How does choline supplementation differ from other treatments for cannabis use during pregnancy?
Choline supplementation is unique because it is a non-drug treatment that focuses on providing an essential nutrient to support fetal brain development and improve cognitive outcomes in children, rather than directly addressing cannabis use. Unlike other treatments, it involves increasing the intake of choline, which is often below recommended levels in pregnant women, to meet the increased demands during pregnancy.12367
Research Team
Sharon Hunter, PhD
Principal Investigator
University of Colorado School of Medicine
M. Camille Hoffman, MD
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for pregnant women who have used cannabis during their current pregnancy. It aims to see if a nutritional supplement, phosphatidylcholine, can improve their baby's brain development in the first 18 months after birth.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either phosphatidylcholine or placebo from approximately 16 weeks gestation through birth
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Choline
Choline is already approved in United States, European Union, Canada for the following indications:
- Dietary supplement
- Dietary supplement
- Dietary supplement
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor